Abstract
The efficacy of classical and molecular therapies in cancer is hampered by the occurrence of primary (intrinsic) and secondary (acquired) refractoriness of tumours to selected therapeutic regimens. Nevertheless, the increased knowledge of the genetic, molecular and metabolic mechanisms underlying cancer results in the generation of a correspondingly increasing number of druggable targets and molecular drugs. Thus, a current challenge in molecular oncology and medicinal chemistry is to cope with the increased need for modelling, both in cellular and animal systems, the genetic assets associated to cancer resistance to drugs. In this review, we summarize the current strategies for generation and analysis of in vitro and in vivo models, which may reveal useful to extract information on the molecular basis of intrinsic and acquired resistance to anticancer molecular agents.
Keywords: Anticancer molecular therapies, tumour, molecular modelling.
Current Medicinal Chemistry
Title:In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Volume: 21 Issue: 14
Author(s): Roberta Rosa, Francesca Monteleone, Nicola Zambrano and Roberto Bianco
Affiliation:
Keywords: Anticancer molecular therapies, tumour, molecular modelling.
Abstract: The efficacy of classical and molecular therapies in cancer is hampered by the occurrence of primary (intrinsic) and secondary (acquired) refractoriness of tumours to selected therapeutic regimens. Nevertheless, the increased knowledge of the genetic, molecular and metabolic mechanisms underlying cancer results in the generation of a correspondingly increasing number of druggable targets and molecular drugs. Thus, a current challenge in molecular oncology and medicinal chemistry is to cope with the increased need for modelling, both in cellular and animal systems, the genetic assets associated to cancer resistance to drugs. In this review, we summarize the current strategies for generation and analysis of in vitro and in vivo models, which may reveal useful to extract information on the molecular basis of intrinsic and acquired resistance to anticancer molecular agents.
Export Options
About this article
Cite this article as:
Rosa Roberta, Monteleone Francesca, Zambrano Nicola and Bianco Roberto, In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies, Current Medicinal Chemistry 2014; 21 (14) . https://dx.doi.org/10.2174/09298673113209990226
DOI https://dx.doi.org/10.2174/09298673113209990226 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP
Current Topics in Medicinal Chemistry Recent Advances on the Enantioselective Synthesis of C-Nucleosides Inhibitors of Inosine Monophosphate Dehydrogenase (IMPDH)
Current Topics in Medicinal Chemistry Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Arsenic Trioxide in Hematological Malignancies: The New Discovery of an Ancient Drug
Current Pharmaceutical Biotechnology Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors
Current Genomics Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology Systemic Fungal Infections Caused by Aspergillus Species: Epidemiology, Infection Process and Virulence Determinants
Current Drug Targets Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond
Clinical Cancer Drugs The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Current Medicinal Chemistry CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Stem Cell Transplantation in Multiple Myeloma
Current Cancer Drug Targets Corticoisteroid-Induced Apoptosis in Hematological Malignancies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials ZEB2 Knock-down Induces Apoptosis in Human Myeloid Leukemia HL-60 Cells
Current Gene Therapy The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets